期刊
BRITISH JOURNAL OF CANCER
卷 123, 期 6, 页码 988-999出版社
SPRINGERNATURE
DOI: 10.1038/s41416-020-0945-0
关键词
-
类别
资金
- Global Core Research Centre (GCRC) Grant from the National Research Foundation (NRF) of Republic of Korea [2011-0030001]
- Basic Science Research Programme through the NRF of Republic of Korea - Ministry of Education [2017R1A6A3A11032154]
- National Research Foundation of Korea [2017R1A6A3A11032154] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Background Gremlin-1 (GREM1), one of the bone morphogenetic protein antagonists, is involved in organogenesis, tissue differentiation and kidney development. However, the role of GREM1 in cancer progression and its underlying mechanisms remain poorly understood. Methods The role of GREM1 in breast cancer progression was assessed by measuring cell viability, colony formation, 3D tumour spheroid formation/invasion and xenograft tumour formation. Chromatin immunoprecipitation, a luciferase reporter assay and flow cytometry were performed to investigate the molecular events in which GREM1 is involved. Results GREM1 expression was elevated in breast cancer cells and tissues obtained from breast cancer patients. Its overexpression was associated with poor prognosis in breast cancer patients, especially those with oestrogen receptor (ER)-negative tumours.GREM1knockdown inhibited the proliferation of breast cancer cells and xenograft mammary tumour growth, while its overexpression enhanced their viability, growth and invasiveness. Oestrogen-related receptor alpha (ERR alpha), an orphan nuclear hormone receptor, directly interacted with theGREM1promoter and increased the expression of GREM1. GREM1 also enhanced the promoter activity ofESRRAencoding ERR alpha, comprising a positive feedback loop. Notably, GREM1 bound to and activated EGFR, a well-known upstream regulator of ERR alpha. Conclusions Our study suggests that the GREM1-ERR alpha axis can serve as a potential therapeutic target in the management of cancer, especially ER-negative tumour.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据